Investigación informativa — no es asesoramiento de inversión. Generado en parte por IA y puede contener errores; no es una recomendación personalizada, solicitud u oferta. ReasyPort no es una empresa de inversión autorizada ni regulada. Los datos de mercado pueden estar retrasados o ser inexactos. El capital está en riesgo y los rendimientos pasados no garantizan resultados futuros — investigue por su cuenta y consulte a un asesor autorizado.
Aviso legal completoReasyPort View: Cautious Watchlist — Cash Conversion Proof Required
Agilent Technologies is not just a laboratory-instrument vendor; it is a workflow-embedded analytical and clinical laboratory platform where instruments seed a recurring stream of services, consumables, software and automation. The business quality is real, but at $127.06 as of the 18 June 2026 close the stock stands about 24% above the selected fair value of $102.09, leaving owners to prove that fiscal 2026 non-GAAP EPS guidance becomes post-capex cash while Agilent funds the approximately $950m pending Biocare acquisition and the September 2026 note maturity without weakening per-share compounding.
The DCF framework uses a 9.25% WACC and 3.0% terminal growth. The conservative downside marker is $89.90, about 29% below the price, and the upside marker is $136.29, about 7% above the price. That means the market is not above the whole underwritten range, but it is already paying for a meaningful step-up from the selected case; the owner is buying execution proof, not a cheap reset.
The key macro issue is not life-science cyclicality in isolation, but whether Agilent’s instrument placements convert into recurring CrossLab economics and post-capex cash: if lab budgets keep funding placements and pull-through, fiscal 2026 growth can support Biocare, debt maturity and shareholder returns; if placements soften and cost recovery lags, guided EPS becomes less defensible and the valuation should stay anchored to cash-conversion proof.
Agilent reported fiscal Q2 2026 revenue of $1.835bn, up 10.0% reported and 6.3% core year over year. GAAP operating margin was 21.7%, non-GAAP operating margin was 26.4%, GAAP net income was $339m, GAAP diluted EPS was $1.20, and non-GAAP EPS was $1.49, up 14% year over year. Management raised fiscal 2026 guidance to revenue of $7.39bn-$7.49bn, 4.5%-6.0% core growth, non-GAAP operating-margin expansion of about 85 bps at the midpoint of core revenue growth, and non-GAAP EPS of $6.00-$6.10; Q3 fiscal 2026 guidance is revenue of $1.83bn-$1.85bn, reported growth of 5.0%-6.5%, core growth of 4.4%-5.9%, and non-GAAP EPS of $1.48-$1.50.
The cash bridge is less generous than the EPS bridge. For the first six months of fiscal 2026, operating cash flow was $545m versus $652m a year earlier; PP&E capex was $169m versus $211m; strict post-capex cash was therefore $376m. Dividends of $144m and buybacks of $217m consumed $361m, leaving only about $15m before acquisitions, debt maturities and other claims. One half-year is not a full-year run-rate, but it is exactly why the cash-conversion proof matters.
Crea una cuenta gratuita para desbloquear el resto del informe y acceder a toda nuestra biblioteca.